REFERENCES
1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918-34.
2. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, et al. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol 1999;93:172-81.
3. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010;7:22-30.
4. Khansari PS, Sperlagh B. Inflammation in neurological and psychiatric diseases. Inflammopharmacology 2012;20:103-7.
5. Whitton PS. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson’s disease. Curr Opin Invest Drugs 2010;11:788-94.
6. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, et al. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharm Biol Psych 2013;42:135-45.
7. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol 2012;7:656-64.
8. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2013;103:853-9.
9. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012;26:469-79.
10. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012;122:1164-71.
11. Blank T, Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013;61:62-70.
12. Shie FS, Chen YH, Chen CH, Ho IK. Neuroimmune pharmacology of neurodegenerative and mental diseases. J Neuroimmune Pharmacol 2011;6:28-40.
13. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, et al. Glial cells in (patho)physiology. J Neurochem 2012;121:4-27.
14. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007;28:138-45.
15. Moynagh PN. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat 2005;207:265-9.
16. John GR, Lee SC, Song X, Rivieccio M, Brosnan CF. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 2005;49:161-76.
17. Sui Y, Stehno-Bittel L, Li S, Loganathan R, Dhillon NK, et al. CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci 2006;23:957-64.
18. Bhattacharya A, Derecki NC, Lovenberg TW, Drevets WC. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology 2016;233:1623-36.
19. Elsayed M, Magistretti PJ. A new outlook on mental illnesses: glial involvement beyond the glue. Front Cell Neurosci 2015;9:468.
20. Pfau ML, Menard C, Russo SJ. Inflammatory mediators in mood disorders: therapeutic opportunities. Annu Rev Pharmacol Toxicol 2018;58:411-28.
21. Sild M, Ruthazer ES, Booij L. Major depressive disorder and anxiety disorders from the glial perspective: Etiological mechanisms, intervention and monitoring. Neurosci Biobehav Rev 2017;83:474-88.
22. Portoghese PS, Larson DL, Sayre LM, Fries DS, Takemori AE. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem 1980;23:233-4.
23. Chen C, Yin J, Riel JK, DesJarlais RL, Raveglia LF, et al. Determination of the amino acid residue involved in [3H] beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem 1996;271:21422-9.
24. Ward SJ, Portoghese PS, Takemori AE. Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther 1982;220:494-8.
25. Liu-Chen LY, Li SX, Tallarida RJ. Studies on kinetics of [3H] beta-funaltrexamine binding to mu opioid receptor. Mol Pharmacol 1990;37:243-50.
26. Davis RL, Buck DJ, Saffarian N, Mohan S, DeSilva U, et al. Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol 2008;3:150-3.
27. Davis RL, Buck DJ, Saffarian N, Stevens CW. The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol 2007;186:141-9.
28. Davis RL, Das S, Buck DJ, Stevens CW. Beta-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes. Neurochem Int 2013;62:478-85.
29. Davis RL, Stevens CW, Thomas Curtis J. The opioid antagonist, beta-funaltrexamine, inhibits lipopolysaccharide-induced neuroinflammation and reduces sickness behavior in mice. Physiol Behav 2017;173:52-60.
30. Garcia-Mesa Y, Jay TR, Checkley MA, Luttge B, Dobrowolski C, et al. Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system. J Neurovirol 2017;23:47-66.
31. Davis RL, Buck DJ, McCracken K, Cox GW, Das S. Interleukin-1β-induced inflammatory signaling in C20 human microglial cells. Neuroimmunol Neuroinflammation 2018;5:50.
32. Davis RL, Dertien J, Syapin PJ. Ethanol-induced modulation of inducible nitric-oxide synthase activity in human A172 astrocytoma cells. Alcohol Clin Exp Res 2002;26:1404-11.
33. Sanchez AC, Davis RL, Syapin PJ. Identification of cis-regulatory regions necessary for robust Nos2 promoter activity in glial cells: indirect role for NF-kappaB. J Neurochem 2003;86:1379-90.
34. Lozano R, Stevens L, Thompson BC, Gilmore KJ, Gorkin R, et al. 3D printing of layered brain-like structures using peptide modified gellan gum substrates. Biomaterials 2015;67:264-73.
35. Mangus LM, Dorsey JL, Laast VA, Hauer P, Queen SE, et al. Neuroinflammation and virus replication in the spinal cord of simian immunodeficiency virus-infected macaques. J Neuropathol Exp Neurol 2015;74:38-47.
36. Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, et al. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychia 2015;16:422-9.
